- Home
- NX vs SYRE Comparison
NX vs SYRE Comparison
Compare NX & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NX
- SYRE
- Stock Information
- Founded
- NX 1927
- SYRE 2013
- Country
- NX United States
- SYRE United States
- Employees
- NX N/A
- SYRE N/A
- Industry
- NX Metal Fabrications
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- NX Industrials
- SYRE Health Care
- Exchange
- NX Nasdaq
- SYRE Nasdaq
- Market Cap
- NX 824.7M
- SYRE 841.4M
- IPO Year
- NX N/A
- SYRE 2016
- Fundamental
- Price
- NX $18.89
- SYRE $16.97
- Analyst Decision
- NX Strong Buy
- SYRE Buy
- Analyst Count
- NX 1
- SYRE 6
- Target Price
- NX $38.00
- SYRE $55.00
- AVG Volume (30 Days)
- NX 370.9K
- SYRE 477.2K
- Earning Date
- NX 06-05-2025
- SYRE 08-06-2025
- Dividend Yield
- NX 1.69%
- SYRE N/A
- EPS Growth
- NX N/A
- SYRE N/A
- EPS
- NX 0.39
- SYRE N/A
- Revenue
- NX $1,625,028,000.00
- SYRE N/A
- Revenue This Year
- NX $48.92
- SYRE N/A
- Revenue Next Year
- NX $3.10
- SYRE N/A
- P/E Ratio
- NX $48.26
- SYRE N/A
- Revenue Growth
- NX 47.66
- SYRE N/A
- 52 Week Low
- NX $15.30
- SYRE $10.91
- 52 Week High
- NX $34.97
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- NX 59.72
- SYRE 65.43
- Support Level
- NX $16.09
- SYRE $15.87
- Resistance Level
- NX $18.25
- SYRE $17.11
- Average True Range (ATR)
- NX 0.77
- SYRE 0.78
- MACD
- NX 0.04
- SYRE 0.23
- Stochastic Oscillator
- NX 48.91
- SYRE 80.00
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.